Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$6,628 Mln
Revenue (TTM)
$2,541 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1
Industry P/E
73.74
EV/EBITDA
-13.1
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$--
EPS
$-78.3
Face value
--
Shares outstanding
5,070,180
CFO
$3,324.47 Mln
EBITDA
$4,405.61 Mln
Net Profit
$6,268.10 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bio-Rad Laboratories
| -23.2 | -- | -5.9 | -13.3 | -22.4 | -11.7 | -- |
|
BSE Sensex*
| 4.0 | -1.2 | 8.0 | 5.3 | 16.6 | 18.9 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Bio-Rad Laboratories
| 1.5 | -20.8 | -44.0 | 25.9 | 55.0 | 60.7 | -3.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bio-Rad Laboratories
|
250.1 | 6,628.2 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 1.0 |
| 13.3 | 8,960.8 | 6,685.2 | 715.6 | 16.4 | 12.3 | 12.6 | 1.5 | |
| 38.4 | 5,823.4 | 3,446.1 | 79.6 | 7.5 | 4.4 | 72.5 | 3.2 | |
| 102.3 | 5,703.2 | 404.5 | -123.7 | -26.1 | -17.3 | -- | 7.5 | |
| 57.4 | 7,968.4 | 2,510.8 | 185.6 | 8.8 | 4.5 | 43.7 | 1.9 | |
| 71.1 | 8,845.4 | 12,669.0 | 407.0 | 5.4 | 11.8 | 22 | 2.7 | |
| 79.0 | 5,391.0 | 1,536.7 | 254.3 | 24.5 | 21.7 | 22.2 | 4.6 | |
| 162.8 | 8,812.8 | 1,973.6 | -494.5 | -11.4 | -41 | -- | 9.3 | |
| 257.0 | 10,106.3 | 1,240.1 | 42.2 | 4.1 | 3.6 | 243.8 | 8.2 | |
| 117.5 | 7,084.1 | 645.7 | -25.4 | 6.8 | -1.3 | -- | 3.6 |
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The... company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. Address: 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 Read more
Chairman, CEO, President & Principal Financial Officer
Mr. Norman D. Schwartz
Chairman, CEO & President
Mr. Norman D. Schwartz
Headquarters
Hercules, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Bio-Rad Laboratories Inc stood at $ 7,000 Mln as on 31-Mar-25
The share price of Bio-Rad Laboratories Inc is $250.08 (NYSE) as of 12-Jun-2025 09:41 EDT. Bio-Rad Laboratories Inc has given a return of -22.43% in the last 3 years.
Bio-Rad Laboratories Inc has a market capitalisation of $ 6,628 Mln as on 12-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Bio-Rad Laboratories Inc is 0.96 times as on 12-Jun-2025, a 72% discount to its peers’ median range of 3.49 times.
Since, TTM earnings of Bio-Rad Laboratories Inc is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bio-Rad Laboratories Inc and enter the required number of quantities and click on buy to purchase the shares of Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. Address: 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547
The CEO & director of Mr. Norman D. Schwartz. is Bio-Rad Laboratories Inc, and CFO & Sr. VP is Mr. Norman D. Schwartz.
There is no promoter pledging in Bio-Rad Laboratories Inc.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
981
|
|
|
921
|
|
|
906
|
|
|
889
|
|
|
823
|
|
|
742
|
|
|
602
|
|
|
567
|
|
|
559
|
| Bio-Rad Laboratories Inc. | Ratios |
|---|---|
|
Return on equity(%)
|
-31.45
|
|
Operating margin(%)
|
-106.31
|
|
Net Margin(%)
|
-87.68
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Bio-Rad Laboratories Inc was $0 Mln.
